Cancer Drug Prices in India: 7 Major Market Shifts in 2026
Analysis India: India’s pharmaceutical industry is approaching an important regulatory transition following the government’s decision to introduce trade margin rationalisation for 137 selected non-scheduled anti-cancer drugs. The National Pharmaceutical Pricing Authority (NPPA) has published revised maximum retail prices for 543 brands, with implementation scheduled for November 9, 2026. This development is expected to influence Cancer
Cancer Drug Prices in India: 7 Major Market Shifts in 2026 Read More »





